These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25166596)

  • 1. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
    Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
    PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
    Butt NA; Kumar A; Dhar S; Rimando AM; Akhtar I; Hancock JC; Lage JM; Pound CR; Lewin JR; Gomez CR; Levenson AS
    Cancer Med; 2017 Nov; 6(11):2673-2685. PubMed ID: 29024573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha.
    Kong X; Lin Z; Liang D; Fath D; Sang N; Caro J
    Mol Cell Biol; 2006 Mar; 26(6):2019-28. PubMed ID: 16507982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study.
    Chong W; Li Y; Liu B; Liu Z; Zhao T; Wonsey DR; Chen C; Velmahos GC; deMoya MA; King DR; Kung AL; Alam HB
    J Trauma Acute Care Surg; 2012 Feb; 72(2):347-53; discussion 353-4. PubMed ID: 22327976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
    Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
    Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma.
    Bhalla S; Evens AM; Prachand S; Schumacker PT; Gordon LI
    PLoS One; 2013; 8(11):e81333. PubMed ID: 24312289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
    Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PX-12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro.
    Akhlaq R; Khan T; Ahmed T; Musharraf SG; Ali A
    Drug Dev Res; 2023 May; 84(3):556-560. PubMed ID: 36808757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1α and hierarchical quality control of pVHL via chaperone system.
    Ni J; Ni A
    PLoS One; 2021; 16(7):e0248019. PubMed ID: 34329303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
    Jonsson M; Ragnum HB; Julin CH; Yeramian A; Clancy T; Frikstad KM; Seierstad T; Stokke T; Matias-Guiu X; Ree AH; Flatmark K; Lyng H
    Br J Cancer; 2016 Oct; 115(8):929-939. PubMed ID: 27599042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the HIF-1alpha stability by histone deacetylases.
    Kim SH; Jeong JW; Park JA; Lee JW; Seo JH; Jung BK; Bae MK; Kim KW
    Oncol Rep; 2007 Mar; 17(3):647-51. PubMed ID: 17273746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
    Zhou X; Yang XY; Popescu NC
    Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.
    Yoo YG; Kong G; Lee MO
    EMBO J; 2006 Mar; 25(6):1231-41. PubMed ID: 16511565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.